BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ariosa Diagnostics, Inc. Release: New Study Demonstrates Non-Invasive Prenatal Testing in High-Risk Women at Price Point of $795 is Clinically Beneficial and Cost-Saving to the Healthcare System


1/29/2013 9:43:55 AM

SAN JOSE, Calif., Jan. 29, 2013 /PRNewswire/ -- A study in the Journal of Maternal-Fetal and Neonatal Medicine highlights the cost-effectiveness of non-invasive prenatal testing (NIPT) with cell-free DNA (cfDNA) in high-risk women. NIPT was shown to have clinical benefit over conventional prenatal screening tests, and at a price point of $795, NIPT demonstrated cost savings to the healthcare system.

(Logo: http://photos.prnewswire.com/prnh/20130129/SF49467LOGO)

In the study, a decision analytic model was used to compare NIPT for trisomy 21, which causes Down syndrome, against conventional prenatal screening with first trimester combined or integrated screening for the U.S. population. While NIPT is not as comprehensive as a karyotype, it does not carry a risk of pregnancy loss. This is the first study to evaluate the economic impact of NIPT in a high-risk pregnancy population as recommended by the American Congress of Obstetricians and Gynecologists (ACOG) and the Society for Maternal Fetal Medicine (SMFM). As compared to conventional prenatal screening, NIPT detected 65-85% more cases of trisomy 21, reduced invasive procedures by over 95%, and in turn, reduced over 99% of unnecessary fetal loss. Details of the study can be found at http://informahealthcare.com/doi/abs/10.3109/14767058.2013.770464

"The clinical advantages of implementing non-invasive prenatal testing into clinical practice are becoming increasingly clear and this model quantifies the benefit," said Dr. Aaron Caughey, senior author of the study and chair of Obstetrics and Gynecology at Oregon Health and Sciences University. "One of the most striking findings is that NIPT can be cost saving to the U.S. healthcare system at the appropriate price. Few, if any, new technologies can demonstrate both clinical and cost benefit. NIPT represents a healthcare advance to achieve the Triple Aim of improved quality, better access, and lower costs."

About Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com. Follow us on Twitter @HarmonyPrenatal and on Facebook at Harmony Prenatal for Healthy Pregnancy.

CONTACT:

Jen Bruursema


Ariosa Diagnostics


408-229-7539


jbruursema@ariosadx.com

SOURCE Ariosa Diagnostics



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES